University South Florida
Welcome,         Profile    Billing    Logout  
 6 Trials 
22 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Currier, Glenn W
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
NCT03622905: ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

Completed
N/A
74
Europe, Canada, US
DBS-f On, DBS Off
Functional Neuromodulation Ltd
Alzheimer Disease
02/24
02/24
Kakar, Rishi
NCT06608641: Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Recruiting
3
490
US
Endoxifen enteric-coated tablet (8 mg), Placebo Tablets
Jina Pharmaceuticals Inc., Novum Pharmaceutical Research Services
Bipolar 1 Disorder
06/25
09/25
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed
2
15
US
ANC-501
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Major Depressive Disorder
08/23
10/23
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Active, not recruiting
2
350
US
LB-102
LB Pharmaceuticals Inc.
Schizophrenia
12/24
05/25
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
NCT06576843: INDV-6001 Multiple-Dose Pharmacokinetic Study

Recruiting
2
122
US
INDV-6001, Suboxone, Sublocade
Indivior Inc.
Moderate to Severe Opioid Use Disorder
10/25
10/25
NCT06051721: A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD)

Recruiting
2
36
US
CYB004, Psychotherapy
Cybin IRL Limited, Worldwide Clinical Trials
Generalized Anxiety Disorder
11/24
02/25
NCT05321602: Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Completed
1
89
US
LY03010 156 mg treatment group, deltoid, paliperidone palmitate, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
09/22
10/22
NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I

Active, not recruiting
N/A
300
Canada, US, RoW
ERG assessment (RSPA)
diaMentis Inc.
Schizophrenia, Bipolar I Disorder
12/24
12/24
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
Bannon, Yvonne
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
NCT05642429: Study of AV-1959D, an Amyloid Beta Vaccine

Recruiting
1
48
US
AV-1959D, Placebo
Institute for Molecular Medicine, National Institute on Aging (NIA), Clinartis
Alzheimer Disease
02/26
11/26
ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting
N/A
100
US
Sham-stimulation, Active-stimulation
Abbott Medical Devices
Treatment Resistant Depression
04/27
04/29
Rosas, Casey
NCT04693351 / 2020-004653-69: Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Active, not recruiting
3
700
Europe, Canada, US, RoW
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
04/25
04/25
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Recruiting
3
2100
Europe, Canada, Japan, US, RoW
Rimegepant/BHV3000, Matching placebo
Pfizer
Pediatric Migraine
01/29
01/29
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

Recruiting
2
300
US
BHV-7000, Placebo
Biohaven Therapeutics Ltd.
Major Depressive Disorder
05/25
07/25
Doran, Robert
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
Kornbluh, Rebecca
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25

Download Options